Tour de France winner Chris Froome in doping shock after failed test during Vuelta
Cycling’s governing body asks Team Sky rider to provide more information after testing positive for twice the permitted level of legal asthma drug
Four-time Tour de France winner Chris Froome failed a doping test during the Vuelta a Espana race in September, cycling’s governing body the UCI said on Wednesday.
The British Team Sky rider had twice the permitted level of legal asthma drug Salbutamol in his body.
The UCI has asked Froome to provide more information but has not suspended him.
Team Sky said Froome had suffered from asthma since childhood and had been affected by symptoms during the Vuelta a Espana, the Tour of Spain, which he went on to win.
But the team said he had taken no more than the allowable amount of Salbutamol.
“During the final week of the Vuelta, Chris experienced acute asthma symptoms,” read a statement. “On the advice of the Team Sky doctor, he used an increased dosage of Salbutamol [still within the permissible doses] in the run-up to the 7 September urine test.”
The team said Froome had declared his use of the medication. “The notification of the test finding does not mean that any rule has been broken,” the statement added.
Froome said the UCI was “absolutely right” to scrutinise the test results. He said that during the race he had “followed the team doctor’s advice to increase my Salbutamol dosage”.
“As always, I took the greatest care to ensure that I did not use more than the permissible dose,” he said. “Together with the team, I will provide whatever information it requires.”
Froome was notified of the test on September 20, the day he finished third in the world time-trial championship in Bergen, Norway.
He has not competed since then, but has announced his intention to try to win the three big tours, in France, Spain and Italy, in 2018.
The test will raise new questions about British cycling following the scandal surrounding the only previous British Tour de France winner, Bradley Wiggins, over his use of so-called therapeutic use exemptions (TUEs).
It emerged that Wiggins received TUEs in order to take a corticosteroid before his three biggest races in 2011, 2012 and 2013, including his 2012 Tour de France win.
Wiggins and Sky have repeatedly denied any wrongdoing, saying the drug was prescribed to treat a long-standing pollen allergy.